research Increasing the Percutaneous Absorption and Follicular Penetration of Retinal by Topical Application of Proretinal Nanoparticles
Proretinal nanoparticles improve skin absorption and reduce irritation of topical retinoids.
Search
forLearn
0 / 0 results — no results
Research
5 / 63 results
research Efficacy and Safety Evaluations of Topical Proretinal Nanoparticles
Proretinal nanoparticles are a safe and effective way to deliver retinal to the skin.
research Does Androgenic Alopecia Aggravate the Risk of Prostate Cancer? Evidence from Mendelian Randomization
Male pattern baldness does not cause an increased risk of prostate cancer.
research Structure Optimization of Tetrahydropyridoindole-Based Aldose Reductase Inhibitors Improved Their Efficacy and Selectivity
Optimizing the structure of a specific compound greatly improved its effectiveness and precision for treating diabetic complications.
research Development of Novel Indole-Based Bifunctional Aldose Reductase Inhibitors and Antioxidants as Promising Drugs for the Treatment of Diabetic Complications
New indole-based compounds, particularly cemtirestat, show promise as dual-function drugs for diabetic complications.
Community Join
5 / 11 resultscommunity Earliest we can get legitimate pyrilutamide
Pyrilutamide, a drug in phase 3 trials in China, potentially becoming available in late 2023 or early 2024; Finasteride being used as a current treatment for hair loss; and the possibility of joining a group buy for black market versions of Pyrilutamide.
community Phase II for Technoderma Therepeutic's TDM-105795 set to begin in April tentatively
Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.
community HMI 115 Phase 1 update: Changes to clinicaltrials.gov page
A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community 1 year progress | 1mg fin daily and topical min twice daily
A user's 1 year progress of using finasteride daily and minoxidil twice daily to treat hair loss, with other users congratulating him on the significant improvement.